Use of Diphenylcyclopropenone for Alopecia Areata Treatment During Pregnancy

April 2024 in “ JAAD Case Reports ”

Deesha Desai, Michael G Buontempo, Ambika Nohria, Lina Alhanshali, Kristen Lo Sicco, Jerry Shapiro

diphenylcyclopropenone alopecia areata alopecia totalis topical immunotherapy DPCP

Studysummary This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

This document presents a case study of a 23-year-old female with alopecia totalis who used diphenylcyclopropenone (DPCP) during her second and third pregnancies, despite medical advice to discontinue. DPCP, a topical immunotherapy, is typically discouraged during pregnancy due to limited safety data. However, the patient experienced significant hair regrowth with no adverse effects or birth defects in her children, who had high APGAR scores. This case suggests potential safety of DPCP during pregnancy, though further studies are needed to confirm its safety profile.

View this study on doi.org →

Discuss this study in the Community →

Research cited in this study

4 / 4 results

research The Invisible Impact Of A Visible Disease: Psychosocial Impact Of Alopecia Areata

40 citations , June 2023 in “Dermatology and Therapy”

This study found that the emotional impact of alopecia areata is significant, but it may not correlate directly with the extent of hair loss since some individuals adapt to the condition.

The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systematic Review and Meta-Analysis

research The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systematic Review and Meta-Analysis

January 2023 in “Dermatologic therapy”

This study reports that diphenylcyclopropenone topical immunotherapy resulted in any hair regrowth for 69% of patients with alopecia areata, but with common side effects including mild to severe contact dermatitis.

research Alopecia Areata Update

244 citations , January 2010 in “Journal of the American Academy of Dermatology”

This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.

research Topical Immunotherapy in Alopecia Areata

45 citations , January 2010 in “International journal of trichology”

This review examines topical immunotherapy for severe alopecia areata, noting that diphencyprone and squaric acid dibutylester are non-mutagenic options with similar efficacy but different practical considerations, and reports no new clinical results.